579 related articles for article (PubMed ID: 15175800)
1. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
2. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.
Walenga JM; Drenth AF; Mayuga M; Hoppensteadt DA; Prechel M; Harder S; Watanabe H; Osakabe M; Breddin HK
Clin Appl Thromb Hemost; 2008 Jul; 14(3):325-31. PubMed ID: 18586683
[TBL] [Abstract][Full Text] [Related]
3. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
Sheth SB; DiCicco RA; Hursting MJ; Montague T; Jorkasky DK
Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
[TBL] [Abstract][Full Text] [Related]
4. Coagulation laboratory testing in patients treated with argatroban.
Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
[TBL] [Abstract][Full Text] [Related]
5. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
[TBL] [Abstract][Full Text] [Related]
6. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
7. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
8. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of Quick/INR values of whole capillary blood (CoaguChek Plus) and venous citrate plasma in patients with and without oral anticoagulation].
Burri S; Demarmels Biasiutti F; Lämmle B; Wuillemin WA
Schweiz Med Wochenschr; 1998 Oct; 128(44):1723-9. PubMed ID: 9846345
[TBL] [Abstract][Full Text] [Related]
10. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Weiss C; Harenberg J
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):605-11. PubMed ID: 15389129
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
13. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
14. Effect of lepirudin on the international normalized ratio.
Stephens JL; Koerber JM; Mattson JC; Smythe MA
Ann Pharmacother; 2005 Jan; 39(1):28-31. PubMed ID: 15590880
[TBL] [Abstract][Full Text] [Related]
15. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
[TBL] [Abstract][Full Text] [Related]
16. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
17. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
Kher A; Gouin I; Samama MM
Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
